Company Encyclopedia
View More
name
Verrica Pharmaceuticals
VRCA.US
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd.
4.514 T
VRCA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking31/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE101.83%A
    • Profit Margin-84.38%E
    • Gross Margin76.90%A
  • Growth ScoreA
    • Revenue YoY234.73%A
    • Net Profit YoY69.39%A
    • Total Assets YoY24.20%A
    • Net Assets YoY49.96%A
  • Cash ScoreB
    • Cash Flow Margin-118.51%D
    • OCF YoY234.73%A
  • Operating ScoreB
    • Turnover0.84B
  • Debt ScoreE
    • Gearing Ratio141.67%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock night trading volatility: Verrica private placement financing of $50 million, stock price soars 7.23% in night trading

    Verrica Pharmaceuticals rose 7.23% in after-hours trading; Eli Lilly rose 0.10% in after-hours trading, with a transaction volume of USD 645,500; Novo Nordisk rose 0.32% in after-hours trading, with a transaction volume of USD 426,300; Pfizer fell 0.04% in after-hours trading, with a transaction volume of USD 254,800

    Tracking Unusual Activity·
    US
    VRCA
    +12.57%
    Tracking Unusual Activity·
    US
    VRCA
    +12.57%

    Verrica Pharmaceuticals Executives Make Significant Stock Purchases

    Executives at Verrica Pharmaceuticals, including Paul B Manning, John J Kirby, Jayson Rieger, and David Zawitz, have made substantial stock purchases, as reported in SEC Form 4 filings. Manning acquired shares worth $17,505,157, Kirby $15,001, Rieger $400,114, and Zawitz $42,425. These transactions reflect significant investments in the company's common stock by its leadership.

    TradingView·
    US
    VRCA
    +12.57%
    TradingView·
    US
    VRCA
    +12.57%

    Officer Rosenberg Buys 2,357 ($10K) Of Verrica Pharmaceuticals Inc [VRCA]

    Rosenberg Noah L Officer of Verrica Pharmaceuticals Inc [VRCA] filed a Form 4 on November 25, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/25/25TransactionPurchaseShares2,357Price$4.24Value$10,000Ending Holdings: 2,357 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    VRCA
    +12.57%
    Reuters·
    US
    VRCA
    +12.57%

    Verrica Pharmaceuticals CMO Noah L. Rosenberg Acquires Common Shares

    Noah L. Rosenberg, Chief Medical Officer of Verrica Pharmaceuticals Inc., has acquired common shares of the company. This information was published by Verrica Pharmaceuticals via the EDGAR system of the U.S. Securities and Exchange Commission.

    Reuters·
    US
    VRCA
    +12.57%
    Reuters·
    US
    VRCA
    +12.57%

    Director and 10% Owner Paul B. Manning Reports Acquisition of Verrica Pharmaceuticals Inc. Common Shares

    Paul B. Manning, a Director and 10% Owner of Verrica Pharmaceuticals Inc., has reported the acquisition of common shares in the company. This information was originally published by Verrica Pharmaceuticals Inc. via the EDGAR system of the U.S. Securities and Exchange Commission on November 25, 2025. The news is for informational purposes and not financial advice.

    Reuters·
    US
    VRCA
    +12.57%
    Reuters·
    US
    VRCA
    +12.57%
    Posts
    View More

    Some + movers in premarket include: $Petco Health and Wellness(WOOF.US) $Urban Outfitters(URBN.US) $Verrica Pharmaceuticals(VRCA.US) $Autodesk(ADSK.US) $Dell Tech(DELL.US) $NetApp(NTAP.US) $Novo Nordi...

    © 2025 Longbridge｜Disclaimer